Ann: H1 2023 Preclinical and Clinical Programs Update, page-90

The need to run the observational trial was something the entire board and Race team agreed was needed. It was not controversial.

I am extremely curious how Race is going to pull the needed cardioprotection data from existing datasets. We spent a massive amount of effort trying to figure out a way of doing this for fairly obvious reasons, but we couldn’t find any studies that had collected all the data required. Some of the needed data is right on the cutting edge of oncology and has only been collected in a few cancer treatment trials. I am even more impatient than ever to see the update.